GammaCan International and Life Therapeutics have announced the signing of a Term Sheet for collaboration to jointly develop VitiGam, an innovative anti-cancer product designed to target metastatic malignant melanoma patients with stage III and IV disease. Advanced stage melanoma represents a large unmet medical need there are no safe and effective therapies available to patients today.
Under the terms, the partners anticipate to share the costs and expenses relating to the development, supply, collection, manufacture, storage, and commercialization of VitiGam as well as their respective portion in any proceeds resulting of the collaboration. Life Therapeutics will also supply plasma to GammaCan for this project. Other terms of the agreement were not disclosed.
"We are extremely pleased to be working with Life Therapeutics on the development of VitiGam for the US and Australian markets," said Patrick Schnegelsberg, CEO of GammaCan. "This brings GammaCan yet another step closer to the planned clinical trials of VitiGam to treat malignant melanoma a cancer with a significant unmet medical need."
Dr Hari Nair, President and CEO of Life Therapeutics said, "We are pleased to be involved in this project and especially so because we are helping to develop a novel life saving therapeutic based on a 'hyper immune' plasma." Once again this establishes Life Therapeutics as the pre-eminent supplier and developer of hyper immune products. The application of hyper immune technology to Vitiligo shows just how broad the applications of this technology are. Dr Nair added that, "this project will be funded jointly by the partners through entities like the BIRD Foundation who recently approved a $1M Grant, subject certain condition, to both parties for the development of VitiGam."
VitiGam is GammaCan's second-generation intravenous IgG-based product and a first-in-class anti-cancer immunotherapy. GammaCan plans on having VitiGam to enter phase I/II testing under a US IND in the near future after it recently held a pre-IND meeting with the FDA.